Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.
Biosimilar Candidate to Humira® Accepted For Review | BI US
Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.
Our innovation strategy focuses on developing a deep understanding of disease, identifying relevant disease mechanisms and using adequate therapeutic modalities to address them
Ridgefield, CT, USA is Boehringer Ingelheim's 3rd largest research sit, where scientists are tackling some of the most difficult challenges in healthcare.
Generalized Pustular Psoriasis: Impact Beyond the Skin
Generalized pustular psoriasis (GPP) is not only about the physical symptoms that impact people living with the condition. GPP goes deeper, beyond the skin.